# Efficacy of Vitex Agnus-castus BNO 1095 (20 mg) in Women With Primary Dysmenorrhea

> **NCT06211049** · PHASE3 · COMPLETED · sponsor: **Bionorica SE** · enrollment: 335 (actual)

## Conditions studied

- Primary Dysmenorrhea

## Interventions

- **DRUG:** Vitex agnus-castus BNO 1095 (20 mg)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06211049
- **Lead sponsor:** Bionorica SE
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-12-12
- **Primary completion:** 2025-07-23
- **Final completion:** 2025-07-23
- **Target enrollment:** 335 (ACTUAL)
- **Last updated:** 2025-07-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06211049

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06211049, "Efficacy of Vitex Agnus-castus BNO 1095 (20 mg) in Women With Primary Dysmenorrhea". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06211049. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*